Suppr超能文献

肝移植或肝切除术后I期和II期肝细胞癌患者的生存分析

Survival analysis of patients with stage I and II hepatocellular carcinoma after a liver transplantation or liver resection.

作者信息

Seshadri Ramanathan M, Besur Siddesh, Niemeyer David J, Templin Megan, McKillop Iain H, Swan Ryan Z, Martinie John B, Russo Mark W, Iannitti David A

机构信息

Hepato-Pancreato-Biliary Surgery, Department of Surgery, Carolinas Medical Center, Charlotte, NC, USA.

出版信息

HPB (Oxford). 2014 Dec;16(12):1102-9. doi: 10.1111/hpb.12300. Epub 2014 Jun 25.

Abstract

INTRODUCTION

Liver transplantation (LT) is a treatment option in select patients with hepatocellular carcinoma (HCC). The aim of the present study was to compare survival in Stage I or II HCC patients undergoing either liver transplant (LT) or a liver resection (LR).

METHOD

The study is a retrospective analysis of the National Cancer Data Base (1998-2011). In total, 148,882 patients with liver cancer were identified, of which 5-year survival data (1998-2006) were available for 64,227 patients. Patients were stratified by the American Joint Committee on Cancer (AJCC) clinical stage I and II. Kaplan-Meier curves and log-rank tests were used for statistical analysis.

RESULTS

3340 HCC patients met analysis criteria. Among stage I HCC, 860 had LT and 871 had LR. Among stage II HCC, 833 had LT and 776 LR. In stage I patients the median survival for LT and LR were 127.9 and 56.7 months, respectively, (P < 0.0001) and in stage II patients the median survival was 110.8 and 42.8 months (P < 0.0001). Unlike LT patients, LR patients with Stage I HCC had a longer median survival compared with Stage II patients (P = 0.0002).

CONCLUSION

Liver transplantation offers a survival advantage compared with a liver resection among patients with Stage I and II HCC. LT is the best surgical treatment for early stage (I/II) HCC in patients with advanced fibrosis or cirrhosis, whereas LR provides equivalent outcomes to LT in patients without advanced fibrosis and should be considered as the first surgical option.

摘要

引言

肝移植(LT)是特定肝细胞癌(HCC)患者的一种治疗选择。本研究的目的是比较接受肝移植(LT)或肝切除术(LR)的I期或II期HCC患者的生存率。

方法

本研究是对国家癌症数据库(1998 - 2011年)的回顾性分析。总共确定了148,882例肝癌患者,其中64,227例患者有5年生存数据(1998 - 2006年)。患者按美国癌症联合委员会(AJCC)临床I期和II期进行分层。采用Kaplan - Meier曲线和对数秩检验进行统计分析。

结果

3340例HCC患者符合分析标准。在I期HCC患者中,860例行LT,871例行LR。在II期HCC患者中,833例行LT,776例行LR。I期患者中,LT和LR的中位生存期分别为127.9个月和56.7个月(P < 0.0001),II期患者中,中位生存期分别为110.8个月和42.8个月(P < 0.0001)。与LT患者不同,I期HCC的LR患者中位生存期比II期患者长(P = 0.0002)。

结论

与肝切除术相比,肝移植在I期和II期HCC患者中具有生存优势。对于有晚期纤维化或肝硬化的患者,LT是早期(I/II)HCC的最佳手术治疗方法,而对于没有晚期纤维化的患者,LR与LT疗效相当,应被视为首选手术方式。

相似文献

10
Recent advances in the surgical treatment of hepatocellular carcinoma.肝细胞癌外科治疗的最新进展
World J Gastroenterol. 2014 Oct 21;20(39):14381-92. doi: 10.3748/wjg.v20.i39.14381.

引用本文的文献

2
A Review of Resection and Surgical Ablation for Primary and Secondary Liver Cancers.原发性和继发性肝癌的切除与手术消融综述
Semin Intervent Radiol. 2024 Jan 24;40(6):536-543. doi: 10.1055/s-0043-1777747. eCollection 2023 Dec.
4
Role of CD147 in the development and diagnosis of hepatocellular carcinoma.CD147 在肝细胞癌发生发展及诊断中的作用。
Front Immunol. 2023 Apr 6;14:1149931. doi: 10.3389/fimmu.2023.1149931. eCollection 2023.

本文引用的文献

4
Hepatocellular carcinoma: resection versus transplantation.肝细胞癌:切除术与移植术。
Semin Liver Dis. 2013 Aug;33(3):282-92. doi: 10.1055/s-0033-1351783. Epub 2013 Aug 13.
6
Hepatocellular carcinoma--resection or transplant?肝细胞癌——切除还是移植?
Nat Rev Gastroenterol Hepatol. 2012 Dec;9(12):732-7. doi: 10.1038/nrgastro.2012.158. Epub 2012 Sep 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验